Three former members of the props department on ABC‘s medical drama Doctor Odyssey filed a lawsuit Friday against the network’s parent company Disney and producer 20th Television, alleging ...

Even the Odyssey logo is subtle and unassuming. The front of the Odyssey G81SF is fairly plain, the bezels are thin but not invisible, they look good. The Samsung logo is tiny and centered at the ...

Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $372.8 million. The company’s full ...

BEDFORD, Mass. (AP) — BEDFORD, Mass. (AP) — Lantheus Holdings Inc. (LNTH) on Wednesday reported first-quarter earnings of $72.9 million. On a per-share basis, the Bedford, Massachusetts-based ...

Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) will be announcing earnings results tomorrow before market open. Here’s what you need to know. Lantheus beat analysts’ revenue ...

Lantheus Price Performance Shares of LNTH stock opened at $107.98 on Tuesday. Lantheus has a one year low of $74.28 and a one year high of $126.89. The company has a market capitalization of $7.39 ...

Brian Markison, CEO Evergreen Theragnostics is expected to add Octevy, a registrational stage PET radiodiagnostic that would complement Lantheus' therapeutic candidate, PNT2003. Both acquisitions ...

The firm has a market cap of $5.66 billion, a P/E ratio of 13.54 and a beta of 0.44. Lantheus has a 52-week low of $56.06 and a 52-week high of $126.89. The business’s 50-day moving average ...

Lantheus will acquire Evergreen Theragnostics for $250 million upfront, plus up to $752.5 million in milestone payments, closing in H2 2025. The Life Molecular Imaging acquisition adds Neuraceq to ...

On a quest to carve out a spot as one of the nuclear medicine greats, Massachusetts-based radiopharmaceutical specialist Lantheus is placing some serious cash on the dealmaking table. In a ...

Lantheus (LNTH) announced a definitive agreement to acquire Evergreen Theragnostics in an all-cash transaction consisting of an upfront payment of $250M and up to an additional $752.5M in ...

Lantheus Holdings is stepping up its game in the radiopharmaceutical space by acquiring Massachusetts-based Evergreen Theragnostics for $250 million upfront. As part of the deal, which was announced ...